A Case of Advanced Hepatocellular Carcinoma with Long-term Post-progression Survival under Repeated Transarterial Chemoembolization after Sorafenib Failure
Journal of Liver Cancer
;
: 82-87, 2017.
Article
in Korean
| WPRIM
| ID: wpr-156764
ABSTRACT
Hepatocellular carcinoma is the third leading cause of cancer related mortality worldwide. Only 30% of patients are eligible for curative surgical resection at diagnosis. For patients with advanced hepatocellular carcinoma with accompanying portal vein tumor thrombosis, Sorafenib is recommended as first-line treatment. However, survival gain from sorafenib is unsatisfactory, and there is no standard therapy for patients who are intolerable or refractory to sorafenib. Here we report a case of a 52-year-old man who initially achieved partial response after sorafenib treatment, but eventually showed disease progression and was treated subsequently with transarterial chemoembolization (TACE). Multinodular recurrence occurred, but he was treated with repeated TACE, and has survived for 4 years so far.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Portal Vein
/
Recurrence
/
Thrombosis
/
Mortality
/
Carcinoma, Hepatocellular
/
Disease Progression
/
Diagnosis
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of Liver Cancer
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS